Literature DB >> 7946860

Rocuronium (Org 9426) for caesarean section.

E Abouleish1, T Abboud, T Lechevalier, J Zhu, A Chalian, K Alford.   

Abstract

This was a prospective, non-randomized, multicentre study of rocuronium (Org 9426) in 40 elective Caesarean section patients at full term without fetal distress. Anaesthesia was induced with thiopentone 4-6 mg kg-1 i.v. and rocuronium 0.6 mg kg-1 and maintained with isoflurane and nitrous oxide in oxygen. Monitors included ECG, arterial pressure, pulse oximeter and train-of-four (TOF) produced by ulnar nerve stimulation. In all patients, full neuromuscular block at the hand indicating the maximum effect of rocuronium (T1 = 0) occurred at a mean time of 98.1 (SE 9.4) s. However, after 79.3 (2.9) s, excellent to good intubating conditions were achieved in 90% of patients. Injection to delivery time was 12.7 (0.9) min and the surgical procedure lasted 53.1 (3.5) min. After administration of rocuronium, T2 appeared after 32.7 (1.8) min (indicating duration of effect). At the end of the surgical procedure in 39 patients, glycopyrronium 0.2 mg and neostigmine 1 mg were given every 5 min to antagonize residual neuromuscular effect. The mean dose of neostigmine required was 1.54 (0.1) mg. Rocuronium had no clinically significant effect on maternal heart rate or arterial pressure. After administration of thiopentone and rocuronium in two patients, temporary erythema occurred, one along the site of injection and the other on the chest wall. Rocuronium had no untoward effects on the neonates, evaluated by 1- and 5-min Apgar scores, time to sustained respiration, total and muscular neuroadaptive capacity scores, acid-base status and blood-gas tensions in umbilical arterial and venous blood.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7946860     DOI: 10.1093/bja/73.3.336

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  15 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  The effects of succinylcholine or low-dose rocuronium to aid endotracheal intubation of adult sows.

Authors:  Tanya Duke-Novakovski; Barbara Ambros; Crissie D Auckland; John C S Harding
Journal:  Can J Vet Res       Date:  2012-01       Impact factor: 1.310

Review 3.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Anesthetic management of the pregnant patient for endovascular coiling of an unruptured intracranial aneurysm.

Authors:  G Allen; P Farling; D McAtamney
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 5.  Clinical pharmacokinetics of neuromuscular relaxants in pregnancy.

Authors:  J Guay; Y Grenier; F Varin
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

6.  [Modified rapid sequence induction for Caesarian sections : case series on the use of rocuronium and sugammadex].

Authors:  D Nauheimer; C Kollath; G Geldner
Journal:  Anaesthesist       Date:  2012-08       Impact factor: 1.041

Review 7.  [New muscle relaxants. Update on mivacurium, rocuronium and cis-atracurium].

Authors:  T Fuchs-Buder
Journal:  Anaesthesist       Date:  1997-04       Impact factor: 1.041

Review 8.  Clinical pharmacokinetics of rocuronium bromide.

Authors:  K S Khuenl-Brady; H Sparr
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 9.  Effects of obstetric analgesics and anesthetics on the neonate : a review.

Authors:  Jay E Mattingly; John D'Alessio; Jaya Ramanathan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Pulmonary valvulotomy in a fetus with pulmonary atresia with intact ventricular septum: First experience in Turkey.

Authors:  Tb Polat; N Danısman
Journal:  Images Paediatr Cardiol       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.